Plain-English translation of NCT07369895 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called O&D-001, which is a type of immunotherapy that uses your own immune cells to fight multiple myeloma — a blood cancer. Researchers have designed these cells to recognize and attack myeloma cancer cells. This is an early-stage study to see if the medication is safe and whether it helps patients whose cancer has come back or stopped responding to other treatments.
Multiple myeloma is a serious blood cancer, and many patients eventually stop responding to standard treatments. This medication represents a new approach using the body's own immune system to attack cancer cells that other treatments can no longer control.
You likely qualify if…
You likely don't qualify if…
You will receive a single intravenous infusion of the medication at the study center. Before treatment, you'll undergo blood tests and other assessments to ensure your organs are healthy enough. The study will monitor you closely for safety, side effects, and how well the treatment works, with follow-up visits and blood work to track your response over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China